{"id":"https://openalex.org/W4283687406","doi":"https://doi.org/10.1080/14737140.2022.2093192","title":"Targeting the PI3K pathway in myeloproliferative neoplasms","display_name":"Targeting the PI3K pathway in myeloproliferative neoplasms","publication_year":2022,"publication_date":"2022-06-28","ids":{"openalex":"https://openalex.org/W4283687406","doi":"https://doi.org/10.1080/14737140.2022.2093192","pmid":"https://pubmed.ncbi.nlm.nih.gov/35763287"},"language":"en","primary_location":{"id":"doi:10.1080/14737140.2022.2093192","doi":"https://doi.org/10.1080/14737140.2022.2093192","is_oa":true,"landing_page_url":"https://doi.org/10.1080/14737140.2022.2093192","pdf_url":null,"source":{"id":"https://openalex.org/S93370067","display_name":"Expert Review of Anticancer Therapy","issn_l":"1473-7140","issn":["1473-7140","1744-8328"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Anticancer Therapy","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1080/14737140.2022.2093192","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023728016","display_name":"Aaron Thomas Gerds","orcid":"https://orcid.org/0000-0002-3422-1309","observed_orcids":["https://orcid.org/0000-0002-3422-1309"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron T Gerds","raw_affiliation_strings":["Cleveland Clinic Taussig Cancer Institute Cleveland","Cleveland Clinic Taussig Cancer Institute Cleveland, Cleveland, OH, USA"],"raw_orcid":"https://orcid.org/0000-0002-3422-1309","affiliations":[{"raw_affiliation_string":"Cleveland Clinic Taussig Cancer Institute Cleveland","institution_ids":["https://openalex.org/I1316902750"]},{"raw_affiliation_string":"Cleveland Clinic Taussig Cancer Institute Cleveland, Cleveland, OH, USA","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059744998","display_name":"Niccol\u00f2 Bartalucci","orcid":"https://orcid.org/0000-0002-9328-3948","observed_orcids":["https://orcid.org/0000-0002-9328-3948"]},"institutions":[{"id":"https://openalex.org/I45084792","display_name":"University of Florence","ror":"https://ror.org/04jr1s763","country_code":"IT","type":"education","lineage":["https://openalex.org/I45084792"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Niccolo Bartalucci","raw_affiliation_strings":["University of Florence","University of Florence, Florence, Italy"],"raw_orcid":"https://orcid.org/0000-0002-9328-3948","affiliations":[{"raw_affiliation_string":"University of Florence","institution_ids":["https://openalex.org/I45084792"]},{"raw_affiliation_string":"University of Florence, Florence, Italy","institution_ids":["https://openalex.org/I45084792"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109421874","display_name":"Albert Assad","orcid":"https://orcid.org/0009-0008-3705-0585","observed_orcids":["https://orcid.org/0009-0008-3705-0585"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Albert Assad","raw_affiliation_strings":["Incyte Corporation","Incyte Corporation, Wilmington, DE, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation","institution_ids":["https://openalex.org/I924451375"]},{"raw_affiliation_string":"Incyte Corporation, Wilmington, DE, USA","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071257161","display_name":"Abdulraheem Yacoub","orcid":"https://orcid.org/0000-0001-5293-4620","observed_orcids":["https://orcid.org/0000-0001-5293-4620"]},"institutions":[{"id":"https://openalex.org/I146416000","display_name":"University of Kansas","ror":"https://ror.org/001tmjg57","country_code":"US","type":"education","lineage":["https://openalex.org/I146416000"]},{"id":"https://openalex.org/I4210097601","display_name":"The University of Kansas Cancer Center","ror":"https://ror.org/00cj35179","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210097601"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Abdulraheem Yacoub","raw_affiliation_strings":["University of Kansas Cancer Center","University of Kansas Cancer Center, Westwood, KS, USA"],"raw_orcid":"https://orcid.org/0000-0001-5293-4620","affiliations":[{"raw_affiliation_string":"University of Kansas Cancer Center","institution_ids":["https://openalex.org/I146416000","https://openalex.org/I4210097601"]},{"raw_affiliation_string":"University of Kansas Cancer Center, Westwood, KS, USA","institution_ids":["https://openalex.org/I4210097601"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5071257161"],"corresponding_institution_ids":["https://openalex.org/I146416000","https://openalex.org/I4210097601"],"apc_list":null,"apc_paid":null,"fwci":0.5235,"has_fulltext":true,"cited_by_count":16,"citation_normalized_percentile":{"value":0.46580696,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"22","issue":"8","first_page":"835","last_page":"843"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.9570000171661377},{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9409999847412109},{"id":"https://openalex.org/keywords/pi3k-signaling","display_name":"PI3K signaling","score":0.9350000023841858},{"id":"https://openalex.org/keywords/pi3kdelta-inhibitor","display_name":"PI3K\u03b4 inhibitor","score":0.8569999933242798},{"id":"https://openalex.org/keywords/parsaclisib","display_name":"parsaclisib","score":0.9879999756813049},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.9300000071525574},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.8669999837875366},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.7599999904632568},{"id":"https://openalex.org/keywords/jak-stat-signaling","display_name":"JAK/STAT signaling","score":0.7929999828338623},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8930000066757202},{"id":"https://openalex.org/keywords/therapeutic-target","display_name":"therapeutic target","score":0.3709999918937683}],"concepts":[{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.9354418516159058},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.806823194026947},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.7008584141731262},{"id":"https://openalex.org/C112392421","wikidata":"https://www.wikidata.org/wiki/Q903451","display_name":"Janus kinase","level":3,"score":0.6758878231048584},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.6583994626998901},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6021451950073242},{"id":"https://openalex.org/C157333092","wikidata":"https://www.wikidata.org/wiki/Q902835","display_name":"JAK-STAT signaling pathway","level":4,"score":0.5214773416519165},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.48438960313796997},{"id":"https://openalex.org/C2777609662","wikidata":"https://www.wikidata.org/wiki/Q416356","display_name":"PTEN","level":4,"score":0.4726613759994507},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.44811397790908813},{"id":"https://openalex.org/C2778277574","wikidata":"https://www.wikidata.org/wiki/Q665327","display_name":"stat","level":4,"score":0.44790738821029663},{"id":"https://openalex.org/C171958077","wikidata":"https://www.wikidata.org/wiki/Q419333","display_name":"STAT protein","level":4,"score":0.4299640953540802},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.3377724587917328},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3235146999359131},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2898753881454468},{"id":"https://openalex.org/C2778923194","wikidata":"https://www.wikidata.org/wiki/Q14912019","display_name":"STAT3","level":3,"score":0.246718168258667},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24329903721809387},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.22206684947013855},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.15875425934791565},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.09691208600997925},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.08496269583702087},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.08077496290206909},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.08055287599563599}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009196","descriptor_name":"Myeloproliferative Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019869","descriptor_name":"Phosphatidylinositol 3-Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019869","descriptor_name":"Phosphatidylinositol 3-Kinases","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D053614","descriptor_name":"Janus Kinase 2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058539","descriptor_name":"Phosphatidylinositol 3-Kinase","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1080/14737140.2022.2093192","doi":"https://doi.org/10.1080/14737140.2022.2093192","is_oa":true,"landing_page_url":"https://doi.org/10.1080/14737140.2022.2093192","pdf_url":null,"source":{"id":"https://openalex.org/S93370067","display_name":"Expert Review of Anticancer Therapy","issn_l":"1473-7140","issn":["1473-7140","1744-8328"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Anticancer Therapy","raw_type":"journal-article"},{"id":"pmid:35763287","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35763287","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert review of anticancer therapy","raw_type":"Journal Article"},{"id":"pmh:oai:flore.unifi.it:2158/1351132","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/2158/1351132","pdf_url":"https://flore.unifi.it/bitstream/2158/1351132/2/Targeting%20the%20PI3K%20pathway%20in%20myeloproliferative%20neoplasms.pdf","source":{"id":"https://openalex.org/S4306402033","display_name":"Florence Research (University of Florence)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I45084792","host_organization_name":"University of Florence","host_organization_lineage":["https://openalex.org/I45084792"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1080/14737140.2022.2093192","doi":"https://doi.org/10.1080/14737140.2022.2093192","is_oa":true,"landing_page_url":"https://doi.org/10.1080/14737140.2022.2093192","pdf_url":null,"source":{"id":"https://openalex.org/S93370067","display_name":"Expert Review of Anticancer Therapy","issn_l":"1473-7140","issn":["1473-7140","1744-8328"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Anticancer Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4283687406.pdf","grobid_xml":"https://content.openalex.org/works/W4283687406.grobid-xml"},"referenced_works_count":42,"referenced_works":["https://openalex.org/W1685529373","https://openalex.org/W1943058608","https://openalex.org/W1972960063","https://openalex.org/W1992477322","https://openalex.org/W2010298229","https://openalex.org/W2030716854","https://openalex.org/W2043993681","https://openalex.org/W2046567666","https://openalex.org/W2078743099","https://openalex.org/W2090642317","https://openalex.org/W2093720054","https://openalex.org/W2115351357","https://openalex.org/W2121743767","https://openalex.org/W2126532431","https://openalex.org/W2127559749","https://openalex.org/W2157066112","https://openalex.org/W2161021913","https://openalex.org/W2165040076","https://openalex.org/W2209579873","https://openalex.org/W2472876886","https://openalex.org/W2589237569","https://openalex.org/W2620018935","https://openalex.org/W2623015358","https://openalex.org/W2744377419","https://openalex.org/W2788853546","https://openalex.org/W2789770437","https://openalex.org/W2904157469","https://openalex.org/W2917721259","https://openalex.org/W2921319668","https://openalex.org/W2945935815","https://openalex.org/W2947357138","https://openalex.org/W2981290006","https://openalex.org/W2996087467","https://openalex.org/W3018806545","https://openalex.org/W3022959153","https://openalex.org/W3097629244","https://openalex.org/W3212937025","https://openalex.org/W3213293168","https://openalex.org/W3217796278","https://openalex.org/W4200583252","https://openalex.org/W4213142561","https://openalex.org/W4231622124"],"related_works":["https://openalex.org/W1990223118","https://openalex.org/W2064453268","https://openalex.org/W3142460753","https://openalex.org/W2046567666","https://openalex.org/W3116778105","https://openalex.org/W2095244598","https://openalex.org/W2106059650","https://openalex.org/W4220869826","https://openalex.org/W7099371233","https://openalex.org/W2075075980"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Decreasing":[1],"efficacy":[2],"over":[3],"time":[4],"and":[5,45,48,83,98,131,153,171,183,201],"initial":[6,172],"suboptimal":[7],"response":[8,60,164],"to":[9,61,94,140,167],"Janus":[10],"kinase":[11,39],"(JAK)":[12],"inhibitors":[13],"such":[14,86],"as":[15,49,87],"ruxolitinib":[16,184],"in":[17,41,54,72,92,113,123,160,191],"a":[18,50,106],"subset":[19],"of":[20,37,59,75,100,110,128,149,156,163,179],"patients":[21,55,206],"are":[22],"critical":[23],"clinical":[24,175,187,193,203],"challenges":[25],"associated":[26],"with":[27,118,207],"myeloproliferative":[28],"neoplasms":[29],"(MPNs),":[30],"primarily":[31],"myelofibrosis.":[32],"AREAS":[33],"COVERED:":[34],"The":[35],"role":[36,108,155],"phosphatidylinositol-3":[38],"(PI3K)":[40],"MPN":[42],"disease":[43],"progression":[44],"treatment":[46,84,170,199],"resistance":[47,166],"potential":[51],"therapeutic":[52,81,138],"target":[53],"who":[56],"experience":[57],"loss":[58,162],"JAK":[62,111,168],"inhibition":[63],"is":[64],"discussed.":[65],"Understanding":[66],"the":[67,73,95,150,154,161,177],"complex":[68],"signaling":[69,90,112,159],"networks":[70],"involved":[71],"pathogenesis":[74],"MPNs":[76],"has":[77],"identified":[78],"potentially":[79],"novel":[80],"targets":[82],"strategies,":[85],"inhibiting":[88],"other":[89],"pathways":[91,133],"addition":[93],"JAK/signal":[96],"transducer":[97],"activator":[99],"transcription":[101],"(STAT)":[102],"pathway.":[103],"PI3K":[104,130,157],"plays":[105],"crucial":[107],"downstream":[109],"rescuing":[114],"tumor":[115],"cell":[116],"proliferation,":[117],"PI3K\u03b4":[119],"being":[120],"particularly":[121],"important":[122],"hematologic":[124],"malignancies.":[125],"Concurrent":[126],"targeting":[127],"both":[129],"JAK/STAT":[132],"may":[134,196],"offer":[135],"an":[136],"innovative":[137],"strategy":[139],"maximize":[141],"efficacy.":[142],"EXPERT":[143],"OPINION:":[144],"Based":[145],"on":[146],"our":[147],"understanding":[148],"underlying":[151],"mechanisms":[152],"pathway":[158],"or":[165],"inhibitor":[169],"results":[173],"from":[174],"studies,":[176],"combination":[178],"parsaclisib":[180,195],"(PI3K\u03b4":[181],"inhibitor)":[182],"holds":[185],"great":[186],"potential.":[188],"If":[189],"confirmed":[190],"larger":[192],"trials,":[194],"provide":[197],"more":[198],"options":[200],"improve":[202],"outcomes":[204],"for":[205],"MPNs.":[208]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-06-30T00:00:00"}